News and Analysis

Invizius inks Series A

Invizius Limited, a developer of treatments to suppress unwanted innate immune responses, has secured 5.3 million pounds in Series A financing.

-

Invizius Limited, a developer of treatments to suppress unwanted innate immune responses, has secured 5.3 million pounds in Series A financing. The investors included Mercia, Downing Ventures, Old College Capital, Scottish Enterprise, Solvay Ventures and Calculus Capital.

Source: Press Release